Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
Sponsor: Texas Tech University Health Sciences Center
Summary
The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2024-11-01
Completion Date
2025-12-01
Last Updated
2025-03-21
Healthy Volunteers
Yes
Conditions
Interventions
Zynrelef
Zynrelef will be injected at the 12mm port site
Exparel
Exparel will be injected at the 12mm port site
Locations (1)
Texas Tech University Health Sciences Center
Lubbock, Texas, United States